Evidence map›Paper›PMID 32862317›Full record

ReviewCurrent treatment options in oncology2020

Health-Related Quality of Life and Patient-Reported Outcomes in Radiation Oncology Clinical Trials.

Jill S Remick, Emily Kowalski, Santanu Samanta, Sung Choi, Joshua D Palmer, Mark V Mishra

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Impact of radiotherapy on quality of life reported by elderly patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Psychometric evaluation of the WHOQOL-BREF and its shorter versions for general Thai population: confirmatory factor analysis and Rasch analysis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jill S RemickDepartment of Radiation Oncology, University of Maryland Medical Center, 22 S. Greene Street, Baltimore, MD, 21201, USA.
Emily KowalskiDepartment of Radiation Oncology, University of Maryland Medical Center, 22 S. Greene Street, Baltimore, MD, 21201, USA.
Santanu SamantaDepartment of Radiation Oncology, University of Maryland Medical Center, 22 S. Greene Street, Baltimore, MD, 21201, USA.
Sung ChoiUniversity of Maryland School of Medicine, Baltimore, MD, USA.
Joshua D PalmerDepartment of Radiation Oncology, The Ohio State University, Columbus, OH, USA.
Mark V MishraDepartment of Radiation Oncology, University of Maryland Medical Center, 22 S. Greene Street, Baltimore, MD, 21201, USA. mmishra@umm.edu.ORCID 0000-0002-2588-1575

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementThe importance of assessing health-related quality of life (HRQoL) and patient-reported outcomes (PROs) is now well recognized as an essential measure when evaluating the effectiveness of new cancer therapies. Quality of life measures provide for a multi-dimensional understanding of the impact of cancer treatment on measures ranging from functional, psychological, and social aspects of a patient's health. Patient-reported outcomes provide for an assessment of physical and functional symptoms that are directly elicited from patients. Collection of PROs and HRQoL data has been shown to not only be feasible but also provide for reliable measures that correlate with established outcomes measures better than clinician-scored toxicities. The importance of HRQoL measures has been emphasized by both patients and clinicians, as well as policy makers and regulatory bodies. Given the benefits associated with measuring HRQoL and PROs in oncology clinical trials, it is increasingly important to establish methods to effectively incorporate PROs and HRQoL measures into routine clinical practice.

Indexed as

Patient Reported Outcome MeasuresQuality of LifeCentral Nervous System NeoplasmsClinical Trials as TopicFemaleGenital Neoplasms, FemaleHead and Neck NeoplasmsHumansMaleNeoplasmsProstatic NeoplasmsRadiation OncologyComparative effectiveness researchPatient-centered outcomesPatient-reported outcomesQuality of lifeRadiation oncologySurvivorship

Identifiers

PMID32862317

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.